[content_protector password=”APC2017″ cookie_expires=”72 hours” identifier=”APCprotectedagenda”]
AGENDA: DAY III
FRIDAY, SEPTEMBER 15, 2017
DAY III CLOSING PLENARY SESSION
(With Simultaneous Chinese/English Translation)
Co-chair Welcome and Introductions
Director, Compliance and Privacy, ASPAC, Ortho Clinical Diagnostics, Singapore (Co-chair)
Key Risks for the Industry and the Future of Ethics and Compliance Programs
APAC Internal Audit Director, AstraZeneca, Shanghai, China
Regional Compliance Officer APAC, Group Compliance, Merck Pte. Ltd., Singapore
Prior to his regional role in Singapore, Albert was also dedicated compliance officer for the Benelux countries and Portugal.
Country Chief Compliance Officer, Novartis Group (China), Shanghai, China
Forensic Partner, Fraud Investigation & Dispute Services, Ernst & Young (China) Advisory Limited, Shanghai, China (Moderator)
Safeguarding Against Bribery and Corruption: Outreach from the Investigating Agencies
Supervisory Special Agent, International Corruption Squad, US Federal Bureau of Investigation, Washington, DC, USA
In 2013, Supervisory Special Agent McEachern was selected to the FBI’s International Corruption Unit where he managed the FBI’s Foreign Corrupt Practices Act (FCPA) global investigations program and helped architect the FBI International Corruption Squads based in Washington, Los Angeles, New York, Miami, Houston, San Francisco, Boston and New Orleans.
Currently, Supervisory Special Agent McEachern supervises the Washington Field Office International Corruption Squad with a focus on FCPA, International Money Laundering, Kleptocracy and Antitrust investigations. Supervisory Special Agent McEachern is a Certified Fraud Examiner (CFE), Certified Anti-Money Laundering Specialist (CAMS), Certified FBI Computer Response Team (CART) Technician and Authorized FBI Digital Extraction Technician (DExT).
New Compliance Challenges: Asia Pac PublicPrivate Pharmaceutical Partnerships
Country Director, China, PATH; Former Commercial Development Director, China, Becton Dickinson; Former Area Sales Manager, China, Boehringer Ingelheim; Former Area, Assistant Manager, China, GSK, Beijing, China
Partner, Arnold & Porter LLP, Washington, DC, USA (Moderator)
Since 2001, Mr. Korenchuk has been included in The Best Lawyers in America. He has developed, led, and implemented “hands-on” educational and healthcare programs that provide pharmaceuticals and healthcare services, teachers, school supplies, library resources, and computers to indigenous communities in South America for the past 12 years.
New Compliance Challenges: Pharmaceutical Compliance and Access to Medicine: Findings on Market Influence and Compliance in the 2016 Access to Medicine Index
Researcher, Access to Medicine Foundation, Amsterdam, The Netherlands
Innovations & New Directions in Compliance – Moving Focus to Ethics & Business Integrity
- Simplification; Culture of Ethics vs. Rule-based compliance
- Use of “Compliance” Ambassadors vs “Integrity” Ambassadors
- Role of Behavioral Economics
- Managing Conflicts of Interest
- How can innovation opportunities in other industry add impact to Ethics & Business Integrity.
- How can we benefit from diverse thinking and ideas to build a highly engaged team culture.
Head, Ethics and Compliance Programs, UCB Pharma; Former Co-chair, Asia Pacific Pharma Compliance Congress, Brussels, Belgium
From 2010 – 2016, Karen was based in Shanghai, China where she built the compliance function for UCB, initially for China and later for the Asia-Pacific region.
Originally from Vancouver, Canada Karen has over 18 years of international work experience in the pharmaceutical industry including clinical operations, quality assurance, auditing & inspections, medical affairs, and business practice compliance. She has focused on business practices, ethics, and compliance topics for the past 10 years.
Managing Principal, Blossom Innovation; Board of Directors, American Chamber of Commerce, Shanghai, Shanghai, China
Vice President, Ethics and Compliance – Lilly China, Eli Lilly and Company, Hong Kong
Vice President, Legal and Compliance, Asia Pacific, Cardinal Health; Former General Counsel and Head of Compliance, Asia Pacific, Allergan, Singapore
He started his career as a solicitor in a leading Singapore law firm, working mainly on corporate matters and cross border commercial transactions, and after thereafter as legal counsel with increasing scope and responsibilities in companies such as Royal Dutch Shell and Halliburton. Gareth has been in legal leadership positions for the last 12 years in the healthcare industry, including Baxter Healthcare, Allergan and now Cardinal Health.
ECLS-Consults (Ethics/Compliance/Legal/Sustainability), Legal/International Compliance and Risk Management Professional, Singapore and Delhi, India; Adjunct Professor, Nanyang Technological University, Singapore & National University Of Singapore; Admitted to practice in Arizona, New Delhi & New York; Former Compliance Officer Life Sciences Industry, Singapore and Delhi, India (Moderator)
Co-chairs Closing Comments